文献检索，用中文搜 PubMed

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

核心技术专利：CN118964589B侵权必究

Yuen K Y, Woo P C Y, Lau S K P

Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong SAR, China.

Hong Kong Med J. 2009 Feb;15 Suppl 2:41-2.

When different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of a neutralising antibody response to SARS-CoV were injected into a mouse model, all the mice immunised with intramuscular tPA-optimised 800 DNA vaccine boosted with intraperitoneal recombinant spike polypeptide generated by Escherichia coli and intramuscular CTLA4Hinge SARS800 DNA vaccine boosted with intraperitoneal S-peptide had neutralising antibody titres of>1:1280.2. This observation may have major practical value for field studies, such as the immunisation of civet cats, as the cost of recombinant proteins produced by E coli is much lower than those produced by eukaryotic systems.3. This study indicates that the type of vaccine used for priming is crucial for determining the type of immune response developed.Subsequent doses will boost the immune response generated by the first dose of vaccine.

当将不同形式的基于严重急性呼吸综合征冠状病毒（SARS-CoV）刺突蛋白的疫苗注射到小鼠模型中以产生针对SARS-CoV的中和抗体反应时，所有用肌肉注射经组织型纤溶酶原激活剂（tPA）优化的800 DNA疫苗免疫并用大肠杆菌产生的腹腔内重组刺突多肽加强免疫的小鼠，以及用肌肉注射细胞毒性T淋巴细胞相关抗原4（CTLA4）铰链SARS800 DNA疫苗免疫并用腹腔内S肽加强免疫的小鼠，其中和抗体滴度均>1:1280。2. 这一观察结果对于野外研究可能具有重大的实际价值，比如对果子狸进行免疫接种，因为大肠杆菌产生的重组蛋白成本远低于真核系统产生的重组蛋白。3. 这项研究表明，用于初次免疫的疫苗类型对于确定所产生的免疫反应类型至关重要。后续剂量将增强第一剂疫苗所产生的免疫反应。

Yuen K Y, Woo P C Y, Lau S K P

Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong SAR, China.

Hong Kong Med J. 2009 Feb;15 Suppl 2:41-2.

When different forms of SARS coronavirus (SARS-CoV) spike protein-based vaccines for generation of a neutralising antibody response to SARS-CoV were injected into a mouse model, all the mice immunised with intramuscular tPA-optimised 800 DNA vaccine boosted with intraperitoneal recombinant spike polypeptide generated by Escherichia coli and intramuscular CTLA4Hinge SARS800 DNA vaccine boosted with intraperitoneal S-peptide had neutralising antibody titres of>1:1280.2. This observation may have major practical value for field studies, such as the immunisation of civet cats, as the cost of recombinant proteins produced by E coli is much lower than those produced by eukaryotic systems.3. This study indicates that the type of vaccine used for priming is crucial for determining the type of immune response developed.Subsequent doses will boost the immune response generated by the first dose of vaccine.

当将不同形式的基于严重急性呼吸综合征冠状病毒（SARS-CoV）刺突蛋白的疫苗注射到小鼠模型中以产生针对SARS-CoV的中和抗体反应时，所有用肌肉注射经组织型纤溶酶原激活剂（tPA）优化的800 DNA疫苗免疫并用大肠杆菌产生的腹腔内重组刺突多肽加强免疫的小鼠，以及用肌肉注射细胞毒性T淋巴细胞相关抗原4（CTLA4）铰链SARS800 DNA疫苗免疫并用腹腔内S肽加强免疫的小鼠，其中和抗体滴度均>1:1280。2. 这一观察结果对于野外研究可能具有重大的实际价值，比如对果子狸进行免疫接种，因为大肠杆菌产生的重组蛋白成本远低于真核系统产生的重组蛋白。3. 这项研究表明，用于初次免疫的疫苗类型对于确定所产生的免疫反应类型至关重要。后续剂量将增强第一剂疫苗所产生的免疫反应。